Labella, R., Ali, A., Mosialou, I., De Angelis, J., Vgenopoulou, P., Zhao, J., Vanderberg, A., Rabadan, R., Raza, A., & Kousteni, S. (2023). 2013 – MESENCHYMAL STROMAL CELL MITOCHONDRIAL TRANSFER FUELS MDS TO AML TRANSFORMATION. Experimental Hematology, 124, S43. https://doi.org/10.1016/j.exphem.2023.06.050

Cordo’, V., Meijer, M. T., Hagelaar, R., de Goeij-de Haas, R. R., Poort, V. M., Henneman, A. A., Piersma, S. R., Pham, T. V., Oshima, K., Ferrando, A. A., Zaman, G. J. R., Jimenez, C. R., & Meijerink, J. P. P. (2022). Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies. Nature Communications, 13(1). https://doi.org/10.1038/s41467-022-28682-1

Zeidan, A. M., Platzbecker, U., Garcia-Manero, G., Sekeres, M. A., Fenaux, P., DeZern, A. E., Greenberg, P. L., Savona, M. R., Jurcic, J. G., Verma, A. K., Mufti, G. J., Buckstein, R., Santini, V., Shetty, J. K., Ito, R., Zhang, J., Zhang, G., Ha, X., Backstrom, J. T., & Komrokji, R. S. (2022). Longer-term benefit of luspatercept in transfusion-dependent lower-risk myelodysplastic syndromes with ring sideroblasts. Blood, 140(20), 2170–2174. https://doi.org/10.1182/blood.2022016171

Lue, J. K., Stevens, D. A., Williams, M. E., Westin, J., Ewesuedo, R., McDonald, A., Agarwal, S., Henrick, P., Perea, R., & Gollob, J. (2022). Phase 1 Study of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. Blood, 140(Supplement 1), 12143–12144. https://doi.org/10.1182/blood-2022-170151

Platzbecker, U., Komrokji, R. S., Fenaux, P., Zeidan, A. M., Sekeres, M. A., Savona, M. R., Madanat, Y. F., Santini, V., Van Eygen, K., Raza, A., Germing, U., Berry, T., Dougherty, S., Shah, S., Sun, L., Huang, F., Feller, F., Wan, Y., Ikin, A., & Sherman, L. (2022). Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study. Blood, 140(Supplement 1), 1106–1108. https://doi.org/10.1182/blood-2022-169050

Mosialou, I., Ali, A. M., Adams, R., Corper, A., Woods, C. M., Fan, X., Raza, A., & Kousteni, S. (2022). Therapeutic Anti-Jagged1 Antibody Targeting Osteoblast-Related Myeloid Dysplasia to Overcome Standard of Care Resistance. Blood, 140(Supplement 1), 2902–2902. https://doi.org/10.1182/blood-2022-167042

Zhou, P., Mansukhani, M. M., Toskic, D., Scalia, S., Lee, L., Wong, S. W., Tuchman, S. A., Hoffman, J. E., Fogaren, T., Varga, C., Lentzsch, S., & Comenzo, R. (2022). Next Generation Sequencing Identifies Light-Chain Amyloid (AL)-Related Igvl Genes in Patients with λ Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM). Blood, 140(Supplement 1), 10048–10049. https://doi.org/10.1182/blood-2022-157790

Tremblay, D., Srisuwananukorn, A., Ronner, L., Podoltsev, N., Gotlib, J., Heaney, M. L., Kuykendall, A., O’Connell, C. L., Shammo, J. M., Fleischman, A., Mesa, R., Yacoub, A., Hoffman, R., Moshier, E., Zubizarreta, N., & Mascarenhas, J. (2022). European LeukemiaNet Response Predicts Disease Progression but Not Thrombosis in Polycythemia Vera. HemaSphere, 6(6), e721. https://doi.org/10.1097/hs9.0000000000000721

Sallman, D. A., Al Malki, M. M., Asch, A. S., Wang, E. S., Jurcic, J. G., Bradley, T. J., Flinn, I. W., Pollyea, D. A., Kambhampati, S. N., Tanaka, T. N., Zeidner, J. F., Garcia-Manero, G., Jeyakumar, D., Gu, L., Tan, A., Chao, M., O’Hear, C., Lal, I., Vyas, P., & Daver, N. (2022). S166: MAGROLIMAB IN COMBINATION WITH AZACITIDINE FOR PATIENTS WITH UNTREATED HIGHER-RISK MYELODYSPLASTIC SYNDROMES (HR MDS): 5F9005 PHASE 1B STUDY RESULTS. HemaSphere, 6, 67–68. https://doi.org/10.1097/01.hs9.0000843556.59348.1d

Akkari, Y. M. N., Baughn, L. B., Dubuc, A. M., Smith, A. C., Mallo, M., Dal Cin, P., Diez Campelo, M., Gallego, M. S., Granada Font, I., Haase, D. T., Schlegelberger, B., Slavutsky, I., Mecucci, C., Levine, R. L., Hasserjian, R. P., Solé, F., Levy, B., & Xu, X. (2022). Guiding the global evolution of cytogenetic testing for hematologic malignancies. Blood, 139(15), 2273–2284. https://doi.org/10.1182/blood.2021014309

Rashkovan, M., Albero, R., Gianni, F., Perez-Duran, P., Miller, H. I., Mackey, A. L., Paietta, E. M., Tallman, M. S., Rowe, J. M., Litzow, M. R., Wiernik, P. H., Luger, S., Sulis, M. L., Soni, R. K., & Ferrando, A. A. (2022). Intracellular Cholesterol Pools Regulate Oncogenic Signaling and Epigenetic Circuitries in Early T-cell Precursor Acute Lymphoblastic Leukemia. Cancer Discovery, 12(3), 856–871. https://doi.org/10.1158/2159-8290.cd-21-0551

Tran, T. H., Langlois, S., Meloche, C., Caron, M., Saint-Onge, P., Rouette, A., Bataille, A. R., Jimenez-Cortes, C., Sontag, T., Bittencourt, H., Laverdière, C., Lavallée, V.-P., Leclerc, J.-M., Cole, P. D., Gennarini, L. M., Kahn, J. M., Kelly, K. M., Michon, B., Santiago, R., … Sinnett, D. (2022). Whole-transcriptome analysis in acute lymphoblastic leukemia: a report from the DFCI ALL Consortium Protocol 16-001. Blood Advances, 6(4), 1329–1341. https://doi.org/10.1182/bloodadvances.2021005634

Menghrajani, K., Gomez-Arteaga, A., Madero-Marroquin, R., Zhang, M.-J., Bo-Subait, K., Sanchez, J., Wang, H.-L., Aljurf, M., Assal, A., Bacher, V. U., Badawy, S. M., Bejanyan, N., Bhatt, V. R., Bredeson, C., Byrne, M., Castillo, P., Cerny, J., Chhabra, S., Ciurea, S. O., … Saber, W. (2022). Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Advances, 6(3), 828–847. https://doi.org/10.1182/bloodadvances.2021004881

Miller, P. G., Qiao, D., Rojas-Quintero, J., Honigberg, M. C., Sperling, A. S., Gibson, C. J., Bick, A. G., Niroula, A., McConkey, M. E., Sandoval, B., Miller, B. C., Shi, W., Viswanathan, K., Leventhal, M., Werner, L., Moll, M., Cade, B. E., Barr, R. G., … Correa, A. (2022). Association of clonal hematopoiesis with chronic obstructive pulmonary disease. Blood, 139(3), 357–368. https://doi.org/10.1182/blood.2021013531

Lieu, Y. K., Liu, Z., Ali, A. M., Wei, X., Penson, A., Zhang, J., An, X., Rabadan, R., Raza, A., Manley, J. L., & Mukherjee, S. (2021). SF3B1 mutant-induced missplicing of MAP3K7 causes anemia in myelodysplastic syndromes. Proceedings of the National Academy of Sciences, 119(1). https://doi.org/10.1073/pnas.2111703119

Gibson, S. E., Liu, Y.-C., Yatsenko, S. A., Barasch, N. J., & Swerdlow, S. H. (2022). Histopathologic, immunophenotypic, and mutational landscape of follicular lymphomas with plasmacytic differentiation. Modern Pathology, 35(1), 60–68. https://doi.org/10.1038/s41379-021-00938-z

Youn, M., Smith, S. M., Lee, A. G., Chae, H.-D., Spiteri, E., Erdmann, J., Galperin, I., Jones, L. M., Donato, M., Abidi, P., Bittencourt, H., Lacayo, N., Dahl, G., Aftandilian, C., Davis, K. L., Matthews, J. A., Kornblau, S. M., Huang, M., Sumarsono, N., … Sakamoto, K. M. (2021). Comparison of the Transcriptomic Signatures in Pediatric and Adult CML. Cancers, 13(24), 6263. https://doi.org/10.3390/cancers13246263

Paolino, J. D., Harris, M. H., Stevenson, K. E., Koch, V., Cole, P. D., Gennarini, L. M., Kahn, J. M., Kelly, K. M., Kirsch, Ii., Michon, B., Place, A. E., Tran, T. H., Welch, J. J. G., & Silverman, L. B. (2021). Performance of Next Generation Sequencing for Minimal Residual Disease Detection for Pediatric Patients with Acute Lymphoblastic Leukemia: Results from the Prospective Clinical Trial DFCI 16-001. Blood, 138(Supplement 1), 3485–3485. https://doi.org/10.1182/blood-2021-152369

Sarkaria, S. M., Bao, S., Zhang, C., & Ding, L. (2021). Comprehensive Cellular Dissection of the Bone Marrow Microenvironment in Primary Myelofibrosis. Blood, 138(Supplement 1), 200–200. https://doi.org/10.1182/blood-2021-153727

De Botton, S., Yee, K., Recher, C., Wei, A. H., Montesinos, P., Taussig, D., Pigneux, A., Braun, T., Curti, A., Esteve, J., Grove, C., Jonas, B. A., Khwaja, A., Legrand, O., Peterlin, P., Arnan Sangerman, M., Blum, W. G., Cilloni, D., Hiwase, D., … Fenaux, P. (2021). Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Blood, 138(Supplement 1), 2351–2351. https://doi.org/10.1182/blood-2021-144912

Garcia, J. S., Wei, A. H., Jacoby, M. A., Fong, C. Y., Borate, U., Baer, M. R., Cunningham, I., Odenike, O., Jurcic, J. G., Nowak, D., Peterlin, P., Platzbecker, U., Dunshee, D., Zhou, Y., Hoffman, D., Sun, Y., Popovic, R., Ainsworth, B., Naqvi, K., … Garcia-Manero, G. (2021). Molecular Responses Are Observed across Mutational Spectrum in Treatment-Naïve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax Plus Azacitidine. Blood, 138(Supplement 1), 241–241. https://doi.org/10.1182/blood-2021-145613

Youn, M., Smith, S. M., Lee, A. G., Chae, H.-D., Spiteri, E., Erdmann, J., Galperin, I., Murphy, L. C., Donato, M., Abidi, P., Bittencourt, H., Lacayo, N. J., Dahl, G., Aftandilian, C., Davis, K. L., Matthews, J. A., Kornblau, S. M., Huang, M., Sumarsono, N., … Sakamoto, K. M. (2021). Gene Expression Analysis of CML Patients across the Age Spectrum. Blood, 138(Supplement 1), 1473–1473. https://doi.org/10.1182/blood-2021-148701

Tremblay, D., Srisuwananukorn, A., Ronner, L., Podoltsev, N., Gotlib, J., Heaney, M. L., Kuykendall, A. T., O’Connell, C. L., Shammo, J. M., Fleischman, A., Mesa, R. A., Yacoub, A., Hoffman, R., Moshier, E., Zubizarreta, N., & Mascarenhas, J. (2021). European Leukemianet (ELN) Response Predicts Disease Progression but Not Thrombosis or Death in Polycythemia Vera (PV): An Analysis of a Multicenter Database. Blood, 138(Supplement 1), 240–240. https://doi.org/10.1182/blood-2021-148020

Pemmaraju, N., Kantarjian, H., Sweet, K., Wang, E. S., Lane, A. A., Ali, H., Stein, A. S., Yacoub, A., Rizzieri, D. A., Vasu, S., Gupta, V., Lee, S., Schiller, G. J., Foran, J. M., Taparia, M. S., Rosenblat, T. L., Walter, R. B., Sieminski, D., Anant, M., … Konopleva, M. (2021). Integrated Safety Analysis of Tagraxofusp, a CD123-Directed Targeted Therapy, in Patients with Hematologic Malignancies. Blood, 138(Supplement 1), 2318–2318. https://doi.org/10.1182/blood-2021-145344

Metheny, L., Callander, N. S., Hall, A. C., Zhang, M.-J., Bo-Subait, K., Wang, H.-L., Agrawal, V., Al-Homsi, A. S., Assal, A., Bacher, U., Beitinjaneh, A., Bejanyan, N., Bhatt, V. R., Bredeson, C., Byrne, M., Cairo, M., Cerny, J., DeFilipp, Z., Perez, M. A. D., … de Lima, M. (2021). Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. Transplantation and Cellular Therapy, 27(11), 923.e1-923.e12. https://doi.org/10.1016/j.jtct.2021.08.010

Dinh, K. N., Jaksik, R., Corey, S. J., & Kimmel, M. (2021). Predicting time to relapse in acute myeloid leukemia through stochastic modeling of minimal residual disease based on clonality data. Computational and Systems Oncology, 1(3). Portico. https://doi.org/10.1002/cso2.1026

Gao, L., Decker, M., Chen, H., & Ding, L. (2021). Thrombopoietin from hepatocytes promotes hematopoietic stem cell regeneration after myeloablation. ELife, 10. CLOCKSS. https://doi.org/10.7554/elife.69894